Funded Tech Companies
IASO Biotherapeutics
Based in Shanghai, IASO Biotherapeutics raised its funding from Housen Care Brothers, EFung Capital and Hongcheng Capital.
Company Overview
Company Name
IASO Biotherapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
5th floor, No. 77-78,Lane 887, Zuchongzhi Road, Shanghai Pil
Shanghai, 201203
CN
Shanghai, 201203
CN
Phone
Website
Email Address
Company Background Information
Overview
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully-human antibody discovery platform (IMARS), high-throughput CAR T drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a diversified portfolio of over 10 novel pipeline products, including IASO's leading asset, Equecabtagene Autoleucel (CT103A), a fully human BCMA chimeric antigen receptor autologous T cell injection. Equecabtagene Autoleucel received New Drug Application (NDA) acceptance from China's National Medical Products Administration (NMPA) for the treatment of relapsed/refractory multiple myeloma (r/r MM).
Last Transaction
1/17/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- Housen Care Brothers
- EFung Capital
- Hongcheng Capital
- Shanghai Guoxin
- Nanjing Jiangbei New Area State-owned Asset Management
- Shanghai Wai Gaoqiao Free Trade Zone United Development
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs